Patent ID: 11905332
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 26:
27. The bispecific antigen-binding molecule of claim 1, wherein the bi-specific antibody has one or more of the following characteristics:
(a) activates human primary T-cells as determined by increase in IL2 release, IFNg release, and T-cell proliferation;
(b) enhances target cell cytotoxicity mediated by a BCMA×CD3 bispecific antibody;
(c) enhances target cell lysis associated with T-cell activation as measured by CD25 upregulation on CD4+ and CD8+ T cells mediated by a BCMA×CD3 bispecific antibody;
(d) enhances target cell lysis associated with T-cell proliferation as measured by dilution of dye in CD4+ and CD8+ T-cells mediated by a BCMA×CD3 bispecific antibody;
(e) enhances cytokine release mediated by a BCMA×CD3 bispecific antibody;
(f) demonstrates decreased tumor burden mediated by a BCMA×CD3 bi-specific antibody in a murine multiple myeloma model;
(g) demonstrates increased survival mediated a by BCMA×CD3 bispecific antibody in a murine multiple myeloma model; or
(h) the first antigen-binding domain binds to CD38 with a dissociation constant (KD) of less than about 10 nM, as measured in a surface plasmon resonance assay.